159 related articles for article (PubMed ID: 26745766)
61. Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors.
North EJ; Howard AL; Wanjala IW; Pham TC; Baker DL; Parrill AL
J Med Chem; 2010 Apr; 53(8):3095-105. PubMed ID: 20349977
[TBL] [Abstract][Full Text] [Related]
62. Considering autotaxin inhibitors in terms of 2D-QSAR and 3D-mapping- review and evaluation.
Katsamakas S; Bermperoglou E; Hadjipavlou-Litina D
Curr Med Chem; 2015; 22(12):1428-61. PubMed ID: 25723504
[TBL] [Abstract][Full Text] [Related]
63. Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions.
Benesch MG; Ko YM; McMullen TP; Brindley DN
FEBS Lett; 2014 Aug; 588(16):2712-27. PubMed ID: 24560789
[TBL] [Abstract][Full Text] [Related]
64. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
65. Evidence for de novo synthesis of lysophosphatidic acid in the spinal cord through phospholipase A2 and autotaxin in nerve injury-induced neuropathic pain.
Ma L; Uchida H; Nagai J; Inoue M; Aoki J; Ueda H
J Pharmacol Exp Ther; 2010 May; 333(2):540-6. PubMed ID: 20123931
[TBL] [Abstract][Full Text] [Related]
66. Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.
Abu El-Asrar AM; Mohammad G; Nawaz MI; Siddiquei MM; Kangave D; Opdenakker G
Acta Diabetol; 2013 Jun; 50(3):363-71. PubMed ID: 22864860
[TBL] [Abstract][Full Text] [Related]
67. Autotaxin overexpression causes embryonic lethality and vascular defects.
Yukiura H; Kano K; Kise R; Inoue A; Aoki J
PLoS One; 2015; 10(5):e0126734. PubMed ID: 25992708
[TBL] [Abstract][Full Text] [Related]
68. Discovery of potent chromone-based autotaxin inhibitors inspired by cannabinoids.
Eymery MC; Nguyen KA; Basu S; Hausmann J; Tran-Nguyen VK; Seidel HP; Gutierrez L; Boumendjel A; McCarthy AA
Eur J Med Chem; 2024 Jan; 263():115944. PubMed ID: 37976710
[TBL] [Abstract][Full Text] [Related]
69. Increased autotaxin activity in multiple sclerosis.
Zahednasab H; Balood M; Harirchian MH; Mesbah-Namin SA; Rahimian N; Siroos B
J Neuroimmunol; 2014 Aug; 273(1-2):120-3. PubMed ID: 24984830
[TBL] [Abstract][Full Text] [Related]
70. Characterization of non-lipid autotaxin inhibitors.
Hoeglund AB; Howard AL; Wanjala IW; Pham TC; Parrill AL; Baker DL
Bioorg Med Chem; 2010 Jan; 18(2):769-76. PubMed ID: 20005724
[TBL] [Abstract][Full Text] [Related]
71. Autocrine lysophosphatidic acid signaling activates β-catenin and promotes lung allograft fibrosis.
Cao P; Aoki Y; Badri L; Walker NM; Manning CM; Lagstein A; Fearon ER; Lama VN
J Clin Invest; 2017 Apr; 127(4):1517-1530. PubMed ID: 28240604
[TBL] [Abstract][Full Text] [Related]
72. Autotaxin is expressed in FLT3-ITD positive acute myeloid leukemia and hematopoietic stem cells and promotes cell migration and proliferation.
Ortlepp C; Steudel C; Heiderich C; Koch S; Jacobi A; Ryser M; Brenner S; Bornhäuser M; Brors B; Hofmann WK; Ehninger G; Thiede C
Exp Hematol; 2013 May; 41(5):444-461.e4. PubMed ID: 23377000
[TBL] [Abstract][Full Text] [Related]
73. Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis.
Oikonomou N; Mouratis MA; Tzouvelekis A; Kaffe E; Valavanis C; Vilaras G; Karameris A; Prestwich GD; Bouros D; Aidinis V
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):566-74. PubMed ID: 22744859
[TBL] [Abstract][Full Text] [Related]
74. ATX and LPA receptor 3 are coordinately up-regulated in lipopolysaccharide-stimulated THP-1 cells through PKR and SPK1-mediated pathways.
Li S; Xiong C; Zhang J
FEBS Lett; 2012 Mar; 586(6):792-7. PubMed ID: 22314276
[TBL] [Abstract][Full Text] [Related]
75. Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish.
Lai SL; Yao WL; Tsao KC; Houben AJ; Albers HM; Ovaa H; Moolenaar WH; Lee SJ
Development; 2012 Dec; 139(23):4439-48. PubMed ID: 23095890
[TBL] [Abstract][Full Text] [Related]
76. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
77. Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity.
Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Tomiya T; Tejima K; Nishikawa T; Arai M; Yanase M; Aoki J; Arai H; Omata M; Fujiwara K; Yatomi Y
Life Sci; 2007 Sep; 81(12):1009-15. PubMed ID: 17850827
[TBL] [Abstract][Full Text] [Related]
78. Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate.
Fisher N; Edwards MG; Hemming R; Allin SM; Wallis JD; Bulman Page PC; Mckenzie MJ; Jones SM; Elsegood MRJ; King-Underwood J; Richardson A
J Med Chem; 2018 Sep; 61(17):7942-7951. PubMed ID: 30059212
[TBL] [Abstract][Full Text] [Related]
79. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
[TBL] [Abstract][Full Text] [Related]
80. Pharmacophoric Site Identification and Inhibitor Design for Autotaxin.
Lee MH; Lee DY; Balupuri A; Jeong JW; Kang NS
Molecules; 2019 Aug; 24(15):. PubMed ID: 31374894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]